Company announces positive data from phase 3 ClarIDHy Study of ivosidenib tablets, first-in-class inhibitor of mutated IDH1 protein, in previously treated IDH1-mutant cholangiocarcinoma patients

Results from the trial (n=185) showed a statistically significant improvement in progression-free survival among patients randomised to ivosidenib tablets vs. placebo patients (HR 0.37; 95% CI 0.25 - 0.54, p<0.0001), with a median PFS of 2.7 months vs. 1.4 months, respectively.

Biospace Inc.